Evidence map›Paper›PMID 38449377›Full record

Trial reportCancer control : journal of the Moffitt Cancer Center

A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma.

Jeremy P Harris, Jino Park, Eric Ku, Steven Seyedin, Russell Stitzlein, Amanda Goldin, Wen-Pin Chen, Christine McLaren, Allen M Chen, Warren Chow

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05488366 (A Pilot Study of Immunotherapy Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05488366 early_phase1active not recruitingnot on this map

A Pilot Study of Immunotherapy Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma

TypeinterventionalSponsorUniversity of California, IrvineRan2022 to 2026Enrolled9ConditionsSarcoma, Soft TissueArmsPembrolizumab, Radiation therapy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. CAR-T cell immunotherapy in rhabdomyosarcoma.Journal of translational medicine · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jeremy P HarrisDepartment of Radiation Oncology, University of California Irvine, Orange, CA, USA.ORCID 0000-0001-7603-0263
Jino ParkDepartment of Radiation Oncology, University of California Irvine, Orange, CA, USA.
Eric KuDepartment of Radiation Oncology, University of California Irvine, Orange, CA, USA.
Steven SeyedinDepartment of Radiation Oncology, University of California Irvine, Orange, CA, USA.
Russell StitzleinDepartment of Orthopaedic Surgery, University of California Irvine, Orange, CA, USA.
Amanda GoldinDepartment of Orthopaedic Surgery, University of California Irvine, Orange, CA, USA.
Wen-Pin ChenBiostatistics Shared Resource, University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, USA.
Christine McLarenBiostatistics Shared Resource, University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, USA.
Allen M ChenDepartment of Radiation Oncology, University of California Irvine, Orange, CA, USA.
Warren ChowDepartment of Medicine, Division of Hematology/Oncology, University of California Irvine, Orange, CA, USA.
University of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

objectivesImmunotherapy with immune checkpoint inhibitors has shown only limited success in the management of metastatic soft tissue sarcoma. Overall response rates (ORR) with single agent pembrolizumab were 18% and median PFS was 18 weeks on the clinical trial SARC028. One strategy to improve the responses to immunotherapy is with stereotactic body radiation therapy (SBRT), which can enhance the antitumor CD8 T cell response through the release of tumor-specific antigens, potentially priming a more diverse class of T cell receptors.

methodsThis is a phase 0, pilot prospective study taking place at a single center with 2 arms. In Arm A, patients are treated with pembrolizumab 400 mg IV infusion on day 1 of a 42-day cycle. Stereotactic body radiation therapy (SBRT) is delivered in 1-5 fractions starting on C1D15-28 and given every other day. In Arm B, patients who have started an immune checkpoint inhibitor within 60 days are treated with SBRT in addition to the current therapy.

resultsIn this study we outline testing the feasibility of adding SBRT to pembrolizumab.

conclusionThe ultimate goal of combination therapy is improved overall response, including tumors not treated with SBRT. This trial can be found registered online: NCT05488366.

Indexed as

Antibodies, Monoclonal, HumanizedNeoplasms, Second PrimaryRadiosurgerySarcomaHumansImmune Checkpoint InhibitorsPilot ProjectsProspective StudiesAntibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitorspembrolizumabimmunotherapypembrolizumabradiationsarcomastereotactic body radiation therapy

Identifiers

PMID38449377
PMCPMC10919132
OpenAlexW4392556319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.